← Back to Search

Other

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

Chula Vista, CA
Phase 2
Waitlist Available
Research Sponsored by Glyscend, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 7, and day 14

Summary

This trial is testing a new diabetes drug to see if it is safe and works better than the current best treatment.

See full description
Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 7, and day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 7, and day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events [Safety and Tolerability of GLY-200]
Secondary study objectives
Change From Baseline in 3-hours Postprandial Plasma Glucose Profile
Change From Baseline in 3-hours Postprandial Plasma Insulin Profile
Change From Baseline in Fasting Glucose
+1 more

Side effects data

From 2023 Phase 2 trial • 51 Patients • NCT05478525
57%
Constipation
14%
Coronavirus Infection
14%
Dyspepsia
14%
Headache
14%
Abdominal Pain
14%
Nausea
7%
Vomiting
7%
Diarrhoea
100%
80%
60%
40%
20%
0%
Study treatment Arm
0.5 g GLY-200
1.0 g GLY-200
2.0 g GLY-200
Pooled Placebo

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: 2.0 g GLY-200Experimental Treatment1 Intervention
2.0 g GLY-200 (4 x 0.5 g capsule) twice a day (BID)
Group II: 1.0 g GLY-200Experimental Treatment1 Intervention
1.0 g GLY-200 (2 x 0.5 g capsule) twice a day (BID)
Group III: 0.5 g GLY-200Experimental Treatment1 Intervention
0.5 g GLY-200 (1 x 0.5 g capsule) twice a day (BID)
Group IV: Placebo for 2.0 GLY-200 armPlacebo Group1 Intervention
4 placebo capsules twice a day (BID)
Group V: Placebo for 0.5 g GLY-200 armPlacebo Group1 Intervention
1 placebo capsule twice a day (BID)
Group VI: Placebo for 1.0 g GLY-200 armPlacebo Group1 Intervention
2 placebo capsules twice a day (BID)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GLY-200
2024
Completed Phase 2
~130

Find a Location

Closest Location:ProSciento, Inc.· Chula Vista, CA

Who is running the clinical trial?

Glyscend, Inc.Lead Sponsor
1 Previous Clinical Trials
75 Total Patients Enrolled
Mark Fineman, PhDStudy ChairGlyscend, Inc.
1 Previous Clinical Trials
75 Total Patients Enrolled
~14 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top